Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

Table 2

Pathologic partial and complete response rates: neoadjuvant chemotherapy.

	Neoadjuvant chemotherapy		Odds ratio (95% CI)*
	Yes	No
Complete response (pT0)			3.11 (1.45–6.64) 𝑃=0.03
Yes	24 (28%)	8 (9%)
No	63 (72%)	83 (91%)
Any response (P ≤ T1)			3.23 (1.21–8.64) 𝑃=0.01
Yes	45 (52%)	23 (25%)
No	42 (48%)	68 (75%)

∗Adjusted for age, gender, race, clinical stage, prior BCG use, extent of TUR, cardiac disease, and baseline creatinine.